Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastrointestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain and analgesics, respiratory, and vitamins, minerals, and nutrients; and contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Revenue projections:

Revenue projections for GLAND
Revenue projections for GLAND

GLAND is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.

Financial Ratios:

currentRatio 0.000000
forwardPE 26.185146
debtToEquity 3.428000
earningsGrowth 0.498000
revenueGrowth 0.074000
grossMargins 0.577280
operatingMargins 0.177140
trailingEps 46.680000
forwardEps 65.010000

GLAND's Forward PE is well-positioned, indicating the stock price is favorable compared to its earnings. This suggests the stock is not overpriced and offers room for growth, making it an attractive option for investors looking for future value appreciation.
GLAND's forward EPS is greater than its trailing EPS, indicating that the company is expected to deliver higher profitability this year. This suggests that GLAND is projected to improve its earnings, reflecting positive growth compared to last year's financial performance.

Price projections:

Price projections for GLAND
Price projections for GLAND

Price projections for Gland Pharma Limited have consistently been revised upward, indicating positive sentiment toward the company. This gradual adjustment reflects growing confidence in Gland Pharma Limited's future potential and financial outlook among analysts.

Insider Transactions:

Insider Transactions for GLAND
Insider Transactions for GLAND


There were 2 GLAND stock sales, with market price at 1987.6499633789062.During the period under review, no sell transactions were recorded.GLAND is seeing more buys than sells at current price levels, which may indicate a positive market outlook. This trend suggests growing confidence among investors, who appear to expect favorable performance from the stock.

Recommendation changes over time:

Recommendations trend for GLAND
Recommendations trend for GLAND


The recent buy bias for GLAND from analysts signals strong confidence in the stock's potential. This positive sentiment could encourage investors to see GLAND as a smart place to invest their money, especially those looking for stable, long-term returns in a well-established company.